Helen W Boucher

Summary

Affiliation: Tufts-New England Medical Center
Country: USA

Publications

  1. ncbi request reprint Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus
    Helen W Boucher
    Division of Infectious Diseases, Tufts New England Medical Center, Boston, MA 02111, USA
    Clin Infect Dis 45:601-8. 2007
  2. doi request reprint Is it possible to blind a trial for community-acquired pneumonia?
    Helen W Boucher
    Division of Infectious Diseases, Tufts University Medical School and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 47:S210-5. 2008
  3. pmc Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients
    Tahaniyat Lalani
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Microbiol 46:2890-6. 2008
  4. doi request reprint Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic
    Sara E Cosgrove
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 48:713-21. 2009
  5. doi request reprint Epidemiology of methicillin-resistant Staphylococcus aureus
    Helen W Boucher
    Division of Infectious Diseases, Tufts University Medical School and New England Medical Center, Boston, Massachussetts, USA
    Clin Infect Dis 46:S344-9. 2008
  6. doi request reprint Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication
    Helen W Boucher
    Division of Infectious Diseases, Tufts University Medical School and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 50:S4-9. 2010
  7. pmc 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America
    Helen W Boucher
    Division of Geographic Medicine and Infectious Diseases, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA
    Clin Infect Dis 56:1685-94. 2013
  8. pmc Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci
    Ana Maria Rivera
    Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA
    Mayo Clin Proc 86:1230-43. 2011
  9. doi request reprint Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
    Helen W Boucher
    Division of Geographic Medicine and Infectious Diseases, Tufts University and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 48:1-12. 2009
  10. ncbi request reprint Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    Vance G Fowler
    Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 355:653-65. 2006

Detail Information

Publications10

  1. ncbi request reprint Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus
    Helen W Boucher
    Division of Infectious Diseases, Tufts New England Medical Center, Boston, MA 02111, USA
    Clin Infect Dis 45:601-8. 2007
    ..Although clinical practitioners must monitor for daptomycin resistance, the available data support the use of daptomycin in the treatment of methicillin-resistant S. aureus bacteremia and endocarditis...
  2. doi request reprint Is it possible to blind a trial for community-acquired pneumonia?
    Helen W Boucher
    Division of Infectious Diseases, Tufts University Medical School and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 47:S210-5. 2008
    ..Particular attention is paid to challenges inherent in the blinding of trials of therapy for pneumonia, especially in trials involving seriously ill patients who require intravenous therapy...
  3. pmc Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients
    Tahaniyat Lalani
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Microbiol 46:2890-6. 2008
    ..In this study of bloodstream isolates collected as part of a multinational randomized clinical trial, USA 300 and pvl-constitutive MRSA strains were associated with better clinical outcomes...
  4. doi request reprint Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic
    Sara E Cosgrove
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 48:713-21. 2009
    ..This study evaluated the association between this practice and nephrotoxicity...
  5. doi request reprint Epidemiology of methicillin-resistant Staphylococcus aureus
    Helen W Boucher
    Division of Infectious Diseases, Tufts University Medical School and New England Medical Center, Boston, Massachussetts, USA
    Clin Infect Dis 46:S344-9. 2008
    ..We examine the trends in both nosocomial and community-associated MRSA infections and explore recent studies of the mechanisms that allow S. aureus to become resistant to currently available drugs...
  6. doi request reprint Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication
    Helen W Boucher
    Division of Infectious Diseases, Tufts University Medical School and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 50:S4-9. 2010
    ..Disease-specific and pathogen-specific indications are discussed, and recent regulatory approvals for bloodstream infection caused by vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus are reviewed...
  7. pmc 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America
    Helen W Boucher
    Division of Geographic Medicine and Infectious Diseases, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA
    Clin Infect Dis 56:1685-94. 2013
    ....
  8. pmc Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci
    Ana Maria Rivera
    Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA
    Mayo Clin Proc 86:1230-43. 2011
    ..In addition, appropriate and aggressive infection control efforts are vital to help prevent the spread of resistant pathogens...
  9. doi request reprint Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
    Helen W Boucher
    Division of Geographic Medicine and Infectious Diseases, Tufts University and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Clin Infect Dis 48:1-12. 2009
    ..This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action...
  10. ncbi request reprint Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    Vance G Fowler
    Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 355:653-65. 2006
    ..Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed...